Although response rate is not a perfect end point, the criteria used should be quoted correctly. The authors state that RECIST defines a partial response as more than 50% tumor shrinkage [1]; in fact, a partial response is defined as a shrinkage of >30%, progressive disease Bortezomib chemical structure is an increase of >20%, and stable disease is a decrease of ≤30% or an increase of ≤20%. The authors have performed a promising study, and their results should be confirmed in larger
prospective trials. Improvements in the management of rare diseases such as clear cell sarcoma can only come through international collaboration. Conflict of interest Dr Robin L. Jones and Dr Anastasia Constantinidou declare no conflict of interest for their submission: “The efficacy of caffeine-potentiated chemotherapy in clear cell sarcoma.” References 1. Karita M, Tsuchiya H, Yamamoto N et al (2011) Caffeine-potentiated chemotherapy for clear cell sarcoma: a report of five cases. Int J Clin Oncol. doi:10.1007/s10147-011-0337-9 2. Kuiper DR, Hoekstra HJ, Veth RP et al (2003) The management of clear cell sarcoma. Eur J Surg Oncol 29(7):568–570PubMedCrossRef 3. Jones RL, Constantinidou A, Thway K et al (2011) Chemotherapy in clear cell sarcoma. Med Oncol
28:859–863″
“Erratum to: Int J Clin Oncol DOI 10.1007/s10147-012-0378-8 The correct name of the fifth author should be given as Akihiko Selleck BMS 354825 Kawahara, not Akihiro Kawahara.”
“The development of molecularly targeted agents has been a key factor in recent advances in
Rebamipide cancer therapy, and some of these agents are now considered standard therapies for various types of carcinoma. The toxicity of molecularly targeted agents is different from that of cytotoxic antitumor agents. ILD in Japanese patients treated with molecular targeting agents has been the focus of many studies. Among tyrosine kinase inhibitors, gefitinib and erlotinib are associated with an increase in the incidence of ILD in Japanese patients. Gefitinib-induced DLI was reported to be 3.5 % in a retrospective analysis and 5.8 % in a prospective study of Japanese patients with non-small-cell lung cancer (NSCLC). In a cohort study including gefitinib and chemotherapy in Japanese patients with NSCLC, the naive cumulative incidence rates at the end of 12-week follow-up were 4.0 % for gefitinib versus 2.1 % for conventional chemotherapy. Little was known about drug-induced ILD when acute ILD-type events developed in Japanese patients treated with molecularly targeted agents including gefitinib. A better understanding of drug-induced ILD is required, including more reliable data about the incidence of events associated with different treatments and identification of the risk factors for this type of ILD.